- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01586039
Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep
Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep.
The timing and quality of sleep is governed by environmental and physiologic factors. Environmental factors, especially ambient lighting can impact the circadian system and alter the timing and structure of sleep. Light exposure can also acutely alter neural activation state and impair sleep. These effects all demonstrate marked sensitivity to short-wavelength blue light with maximal sensitivity in the 460-480 nm range. The alerting effects of blue light in the evening persist for at least 3-4 hours after the lights are turned off, and can disturb subsequent sleep. Avoiding these deleterious effects of light exposure prior to sleep on subsequent sleep would be beneficial to sleep quality and potentially health.
The investigators will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light. The investigators will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL). In a within-subject design, the investigators will test the hypotheses that exposure to a blue-depleted LED as compared to a CFL exposure at (1) 90 lux or (2) 50 lux will cause significantly:
- Less melatonin suppression between melatonin onset and bedtime;
- Less subjective and objective alerting responses before bedtime;
- Less disruption of nocturnal sleep structure and quality.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham and Women's Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
(i) Aged between 18-30 years to reduce the confounding effects of lens aging on the transmission of light to the retina;
(ii) Non-smoking for at least 6 months;
(iii) Healthy (no medical, psychiatric or sleep disorders);
(iv) No clinically significant deviations from normal in medical history, vital signs, physical examination, blood chemistry and hematology, urine chemistry and ECG;
(v) Women of childbearing potential must agree to use an acceptable method of birth control, and must have a negative urine pregnancy test;
(vi) Body mass index of > 18 or < 30 kg/m2;
(vii) No drugs or medication likely to affect sleep or alertness, as determined by the investigators;
(viii) Habitual caffeine consumption < 300mg per day on average;
(ix) Habitual alcohol consumption < 10 alcoholic units per week on average.
Exclusion Criteria:
(i) History of alcohol or substance abuse;
(ii) Positive result on drugs of abuse screening;
(iii) Current or past history of sleep disorders, including but not limited to obstructive sleep apnea, or any significant sleep complaint;
(iv) Psychiatric disorder;
(v) Recent acute or chronic medical disorder, including but not limited to hepatic impairment and severe chronic obstructive pulmonary disease;
(vi) Visual disorder, including but not limited to color blindness, or family history of glaucoma;
(vii) History of intolerance or hypersensitivity to melatonin or melatonin agonists;
(viii) Pregnancy or lactation;
(ix) Shift work;
(x) Transmeridian travel (2 or more time zones) in past 2 months;
(xi) Any other reason as determined by the Principal Investigator.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Fakultätszuweisung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Compact Fluorescent Light 90 lux
90 lux exposure of a commercially available Compact Fluorescent Light (CFL).
|
We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime.
We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
Experimental: Blue-depleted LED light 90 lux
90 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime.
We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
Aktiver Komparator: Compact Fluorescent Light 50 lux
50 lux exposure of a commercially available Compact Fluorescent Light (CFL).
|
We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime.
We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
Experimental: Blue-depleted LED light 50 lux
50 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime.
We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Melatonin Suppression
Zeitfenster: 6-h constant posture interval of the light exposure
|
Melatonin suppression is measured as the percentage of melatonin AUC relative to the AUC measured in dim light on the previous day.
AUC was calculated during the 6 h of light exposure and the corresponding 6-h interval 24 hours earlier.
Higher values indicate more light-induced melatonin suppression.
|
6-h constant posture interval of the light exposure
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Sleep Structure
Zeitfenster: 8-h time in bed immediately following CFL/LED light exposure.
|
Sleep efficiency assessed by polysomnography.
Sleep efficiency refers to the percentage of time a person sleeps, in relation to the amount of time a person spends in bed trying to sleep.
The percentage is calculated by dividing the Total Sleep Time by the Total Time in Bed.
|
8-h time in bed immediately following CFL/LED light exposure.
|
Sleep Quality
Zeitfenster: First morning after 8-h time in bed immediately following CFL/LED light exposure.
|
Self-reported sleep quality was assessed using a post sleep questionnaire.
Score on subjective scale range 1-7, higher scores indicate higher sleep quality.
|
First morning after 8-h time in bed immediately following CFL/LED light exposure.
|
Subjective Alerting Response
Zeitfenster: 6-h constant posture interval of the light exposure.
|
Self-reported sleepiness measured during the light exposure using the Karolinska Sleepiness Scale (KSS).
Range of scores 1-9, higher score indicate higher subjective sleepiness.
Measures were taken hourly throughout the 6-hour constant posture interval of the light exposure and then averaged to calculate a single value per participant.
|
6-h constant posture interval of the light exposure.
|
Objective Alerting Response
Zeitfenster: 6-h constant posture interval of the light exposure
|
Mean reaction time assessed using the 10-minute psychomotor vigilance test.
Higher numbers indicate slower reaction times indicating less alertness.
Measures were taken hourly throughout the 6-hour constant posture interval of the light exposure and then averaged to calculate a single value per participant.
|
6-h constant posture interval of the light exposure
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Steven W Lockley, Ph.D., Brigham and Women's Hospital; Harvard Medical School
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 2011-P-002834
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Non-visual Photoreception
-
University of ZurichUSZ FoundationAktiv, nicht rekrutierend
-
Guy's and St Thomas' NHS Foundation TrustNoch keine RekrutierungVisual Snow-Syndrom
-
University of Colorado, DenverAbgeschlossenVisual Snow-SyndromVereinigte Staaten
-
Universitaire Ziekenhuizen KU LeuvenAbgeschlossen
-
Fondation Ophtalmologique Adolphe de RothschildZurückgezogenVisual Snow-SyndromFrankreich
-
Guy's and St Thomas' NHS Foundation TrustAbgeschlossenVisual Snow-Syndrom | Photophobie | Schleppphänomen | Visuelle AuraVereinigtes Königreich
-
Stanford UniversityNational Institutes of Health (NIH); AmgenAbgeschlossenLymphom, Non-Hodgkin | Lymphome: Non-Hodgkin | Lymphome: Periphere Non-Hodgkin-T-Zelle | Lymphome: Kutanes Non-Hodgkin-Lymphom | Lymphome: Non-Hodgkin Diffuse Large B-Zell | Lymphome: Non-Hodgkin Follikel / indolente B-Zelle | Lymphome: Non-Hodgkin-Mantelzelle | Lymphome: Non-Hodgkin-Randzone | Lymphome...Vereinigte Staaten
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Noch keine RekrutierungLymphom | Lymphom, Non-Hodgkin | Non-Hodgkin-Lymphom | Non-Hodgkin-Lymphom | Refraktäres B-Zell-Non-Hodgkin-Lymphom | Refraktäres Non-Hodgkin-Lymphom | Hochgradiges B-Zell-Lymphom | ZNS-Lymphom | Lymphome Non-Hodgkin-B-Zelle | Rezidiviertes Non-Hodgkin-Lymphom | Lymphom, Non-Hodgkins | Großes B-Zell-Lymphom | Lymphom, Non-Hodgkin, Erwachsener und andere Bedingungen
-
Marker Therapeutics, Inc.RekrutierungNon-Hodgkin-Lymphom | Non-Hodgkin-Lymphom, Erwachsener | Non-Hodgkin-Lymphom, refraktär | Non-Hodgkin-Lymphom, rezidiviertVereinigte Staaten
-
Mayo ClinicNoch keine RekrutierungIndolentes B-Zell-Non-Hodgkin-Lymphom | Rezidivierendes indolentes Non-Hodgkin-Lymphom | Refraktäres indolentes Non-Hodgkin-Lymphom | Rezidivierendes indolentes B-Zell-Non-Hodgkin-Lymphom | Refraktäres indolentes B-Zell-Non-Hodgkin-LymphomVereinigte Staaten
Klinische Studien zur Visible light
-
RxSight, Inc.Abgeschlossen
-
RxSight, Inc.RekrutierungKatarakt | AphakieVereinigte Staaten
-
Dent Neuroscience Research CenterGenentech, Inc., a subsidiary of F. Hoffman-La Roche AG; Monogram Biosciences...Noch keine RekrutierungMultiple Sklerose | Schubförmig remittierende Multiple Sklerose
-
Calhoun Vision, Inc.AbgeschlossenKataraktVereinigte Staaten
-
RxSight, Inc.Abgeschlossen
-
LumiThera, Inc.RekrutierungTrockene altersbedingte MakuladegenerationNorwegen
-
LumiThera, Inc.National Eye Institute (NEI)RekrutierungTrockene altersbedingte MakuladegenerationVereinigte Staaten
-
Elastagen Pty LtdAbgeschlossenIntrinsische Alterung der HautAustralien
-
M.D. Anderson Cancer CenterBeendetFortgeschrittene KrebsartenVereinigte Staaten
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeAbgeschlossenBrustkrebs weiblichVereinigte Staaten